BioSpace News Archive

Instil Bio, Inc. reported two poster presentations at the SITC 2023 Annual Meeting demonstrating that its proprietary CoStimulatory Antigen Receptor platform enhances the activity of CD4+ T cells across multiple axes.

Biotheus Inc. (“Biotheus”) today announced that the company has entered into an exclusive global license and collaboration agreement under which BioNTech will be developing, manufacturing and commercializing PM8002 globally ex-Greater China, whereas Biotheus retains the rights to exploit PM8002 in Greater China.

Karyopharm Therapeutics Inc. announced the presentation of updated long-term safety and efficacy data from a pre-specified exploratory subgroup analysis of the SIENDO study in patients with advanced or recurrent TP53 wild-type endometrial cancer at the International Gynecological Cancer Society Annual Global Meeting in Seoul, South Korea.

Orthofix Medical Inc., a leading global spine and orthopedics company, announced the full U.S. commercial launch of the WaveForm® L Lateral Lumbar Interbody System.

AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, announced that company management will participate in two upcoming investor conferences in November.

Volastra Therapeutics, a clinical-stage cancer biotechnology company, today announced the appointment of David Nicholson, Ph.D., as an independent member of its Board of Directors.

Biogen Inc. announced the appointment of Monish Patolawala, currently President and Chief Financial Officer of 3M Company, to the Company’s Board of Directors, effective January 1, 2024.

Spero Therapeutics, Inc. (Nasdaq: SPRO) today announced that it will host a conference call and live audio webcast on Monday, November 13, 2023 at 4:30 p.m. ET to report its third quarter 2023 financial results and provide an update on its business and pipeline.

Biora Therapeutics, Inc today announced it will report financial results and provide a corporate update for the third quarter ended September 30, 2023.

Keros Therapeutics, Inc. today provided a business update and reported financial results for the quarter ended September 30, 2023.